Summary
Thirty adults with proved typhoid fever were treated with amoxycillin 1 g six-hourly by mouth for an average of 14 days because of haematological contraindications to chloramphenicol. Eighteen patients were Egyptian men with the Mediterranean variety of glucose-6-phosphate dehydrogenase deficiency and an enzyme activity in the red cells ranging from 0 to 3%, and 12 patients had a history of severe but reversible myelosuppression after eight to 12 days' treatment with chloramphenicol 1 5-2 g daily. The clinical and bacteriological responses in this group of patients were compared with those of 30 haematologically normal patients of comparable age and sex treated with chloramphenicol.
The results showed that amoxycillin is an effective alternative to chloramphenicol for treating typhoid fever in patients with haematological contraindications to chloramphenicol.
Introduction
Although typhoid fever is not endemic in Egypt, it is a common cause of pyrexia of undetermined origin in adult Egyptians. This fact is overemphasised by general practitioners, who usually start treating patients with pyrexia of undetermined origin with chloramphenicol before the laboratory tests for the diagnosis of enterica have proved or disproved the presumptive diagnosis of typhoid fever. This, together with the prevailing practice by These two facts prompted us to carry out a clinical trial of an alternative drug that could replace chloramphenicol in the treatment of typhoid fever in these patients. Amoxycillin (D(-)a-amino-p-hydroxybenzylpenicillin trihydrate) 1 g sixhourly was chosen for the trial in view of its safety and its considerably higher serum concentrations than ampicillin.8 Reports have shown the success of amoxycillin in treating typhoid fever in several groups of patients. 46 We believed that running a clinical trial of amoxycillin in the treatment of typhoid fever in these two groups of patients was justifiable.
Patients and methods
Thirty adults suffering from typhoid fever and ranging in age from 16 to 38 years were included in the trial. Eighteen were men suffering from severe Mediterranean glucose-6-phosphate dehydro-genase deficiency. The enzyme assay for these patients, carried out by the method of Glock and McLean, showed either no enzyme activity or an activity below 0 01 units, which is less than 3% of the normal activity. The remaining 12 patients had developed a transient episode of bone marrow hypoplasia three to eight weeks after a course of chloramphenicol. The daily dose of chloramphenicol was 1-5 to 2 g; and the course lasted from 8 to 12 days. The 12 patients, who all showed marrow hypoplasia and vacuolation of the normoblasts, developed moderate anaemia with a haemoglobin level of 8-6-10 g/ dl and leucopenia with a neutrophil count below 1-5 x 109/1 (1500/ mm3). Five also developed thrombocytopenia with a platelet count below 100 x 109/1 (100 000/mm3). The 12 patients recovered from the hypoplastic episode after eight to 14 weeks' treatment in the haematology unit.
Before the start of specific treatment blood, urine, and stool samples were taken. The diagnosis of typhoid fever was confirmed in all the patients by a positive blood culture for Salmonella typhi and treatment with amoxycillin was delayed until the blood culture results were known.
Complete blood picture; urine and stool examination including examination for S typhi; Widal test, liver function tests including measurement of serum bilirubin, serum aspartate transaminase, and alkaline phosphatase; and serum electrolyte and blood urea estimations were carried out for all the patients. Patients with glucose-6-phosphate dehydrogenase deficiency underwent daily estimation of their haemoglobin concentration and serum bilirubin level during the period of fever. Blood culture for S typhi was repeated every five days from the date of the diagnosis up to 15 days after the temperature dropped to normal. Amoxycillin was given by mouth in a dose of 1 g six-hourly for 12-16 days (mean 14 days), after which the blood picture was repeated and serum bilirubin measured weekly for two weeks. The same laboratorv tests were carried out in 30 haematologically normal patients aged 17 to 40 years who were treated with chloramphenicol 1 g eight-hourly until defervescence followed by 500 mg six-hourly for one week thereafter.
Results
Clinical response was judged by relief of toxicity, improvement in wellbeing, return of appetite, and finally drop of temperature to 37 5°C or less. Twenty-four patients showed striking clinical improvement after three to five days, five improved after six to eight days, and one improved after 12 days. Settlement of temperature to 37-50C or less lagged two to three days after the onset of the clinical improvement. The haemoglobin level in the 12 patients suffering from glucose-6-phosphate dehydrogenase deficiency did not drop by more than 1-8 g/dl during the period of fever and the serum bilirubin concentration did not rise by more than 18-8 umol/l (141 mg/100 ml) from the pretreatment values (table I) . This indicated mild or moderate haemolytic processes. Table II shows the clinical and bacteriological response pattern in the patients treated with amoxycillin compared with that of the 30 normal patients treated with oral chloramphenicol. 9-6 8-4-9-2 35-9 42-8-54-7 10 11-6 10-7-11 0 13-7 20-5-34-2 11 10-7 9-6-10-4 23-9 27-4-42-8 12 10-0 8-4-9-6 34-2 42-8-53-0
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The incidence of relapse, defined as a recurrence of symptoms after initial response and reisolation of S typhi on blood culture, was also compared in both groups, together with the incidence of the other common complications (see table II ). 
Discussion
The two groups of patients included in the trial suffered from different haematological abnormalities, but they both shared the common problem of developing predictable and serious haematological complications on administration of chloramphenicol. The gravity of the complications makes the doctor hesitate before deciding on giving chloramphenicol to these patients even when chloramphenicol is the most effective specific antimicrobial agent, as was the case with typhoid fever a few years ago.
In severe Mediterranean glucose-6-phosphate dehydrogenase deficiency the red cells undergo haemolysis either spontaneously or with mild infection because of their low or absent enzyme activity. It is important to emphasise that the synergic action between glucose-6-phosphate dehydrogenase deficiency and infection in the pathogenesis of haemolysis may turn benign haemolysis produced by a drug such as chloramphenicol into a severe haemolysis. The haemolytic episode might even be life threatening and require blood transfusion, since men with homozygous inheritance of Mediterranean glucose-6-phosphate dehydrogenase deficiency have only a single population of grossly enzyme-deficient red cells that undergo extensive haemolysis on exposure to two challenging agents.
The drop in haemoglobin concentration in the glucose-6-phosphate dehydrogenase deficient patients during the toxaemic period of the disease did not result in life-threatening anaemia demanding blood transfusion, as the maximum drop did not exceed 1-8 g/dl. This was partly due to-the efficacy of amoxycillin in rapidly controlling the iactivity of the disease, even faster than chloramphenicol, thus reducing the time during which the vulnerable red cells were exposed to the lethal toxaemia, and partly due to the absolute safety of the drug both to the regenerative erythroid activity of the bone marrow and to the newly formed red cell population.
In the second group of patients, who showed idiosyncratic myelosuppression and normoblastic vacuolation on previous intake of chloramphenicol, the degree of risk of exposing the marrow to the hazard of chloramphenicol is unpredictable and might exceed in its gravity the previous episode, possibly even causing irreversible aplasia. It is therefore wise to consider that the administration of chloramphenicol is absolutely contraindicated in these patients.
In view of the greater effectiveness of amoxycillin compared with chloramphenicol, amoxycillin should be considered as the drug of choice for treating typhoid fever in patients with haematological contraindications to chloramphenicol.
